Companies/US/IBRX

IMMUNITYBIO, INC.

Income flow

Annual
IBRX 10-K Income StatementPeriod 2025-12-31Source 10-K
Net sales$113M+668% Y/YRevenue$113M+668% Y/YGross profit$113M+663% Y/YCost of revenue$753,000

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0Shares outTotal shares currently outstanding (issued and not retired).1.06BFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).406.7M